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Summary A handful of Henoch—Scho¨nlein purpura (HSP) cases have been reported in HIV-
infected adult patients. We report herein the case of an 11-year-old Thai girl with HIV infection,
who developed severe abdominal pain and palpable purpura consistent with HSP, 3 months after
planned antiretroviral treatment interruption (PTI). One month later she developed thrombo-
cytopenia. It is possible that an HIV effect on vascular endothelium or PTI-associated immune
activation contributed to HSP and thrombocytopenia.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Henoch—Scho¨nlein purpura (HSP) is a systemic disorder char-
acterized by leukocytoplastic vasculitis involving small vessels
of the skin, gastrointestinal tract, joints, and kidneys. A few
cases of HSP in adults with HIV have been reported.1,2 A study
from China has recently reported two out of 98 HIV-infected
cases with HSP.3 Over half of these patients had some type of
rheumatologic disorder and the majority had low CD4 counts
andhepatitis Cvirus (HCV)co-infection.Hepatitis B virus (HBV)
co-infectionwasalso reported in a JapaneseHIV-infectedmale* Corresponding author. Tel.: +66 2 255 7335; fax: +66 2 252 5779.
E-mail address: torsak.b@hivnat.org (T. Bunupuradah).
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doi:10.1016/j.ijid.2008.05.1225who hadHSPand nephritis. His clinical conditionwas improved
after starting antiretroviral therapy.4
Planned antiretroviral treatment interruption (PTI) guided
byCD4%or count is a non-standardHIV treatment strategy that
aims to safely stop antiretroviral therapy (ART) in order to
improve quality of life and reduce ART toxicity. Both HIV and
PTI have been associatedwith immune activation and immune
complex development, which may contribute to HSP. We
report herein the case of an 11-year-old girlwithHIV infection,
who developed HSP and thrombocytopenia after PTI.
Case report
An 11-year-old girl with HIV infection was hospitalized for
severe colicky abdominal pain and palpable purpura on thePublished by Elsevier Ltd. All rights reserved.
e32 T. Bunupuradah et al.thighs, abdominal wall, and arms, 3 months after PTI. Five
years earlier, she had been diagnosed with perinatally
acquired HIV infection. She was Centers for Disease Control
and Prevention (CDC) clinical classification B with asympto-
matic thrombocytopenia (platelet count of 69  109/l).
Before starting ART, her CD4% was 11% and CD4 count was
155 cell/mm3. She had been successfully treated with sta-
vudine, lamivudine, and nevirapine for 4.7 years. She had
expressed discontent with taking ART and her caregiver was
concerned about future non-adherence. She underwent a PTI
with the goal of restarting her ART if her CD4 fell below 20% or
350 cells/mm3. Before the PTI, her plasma HIV-RNA level was
<50 copies/ml and CD4 was 32% and 800 cells/mm3. She had
a normal platelet count of 264  109/l.
She was well until 3 months after PTI when she experi-
enced severe colicky abdominal pain and palpable purpura
on the thighs, abdominal wall, and arms (Figure 1) without
melena, hematuria, or arthritis. She was hospitalized, and
work-up, including complete blood count, platelet count,
anti-nuclear antibody, anti-double-stranded DNA, C3, crea-
tinine, serum aminotransferase, bilirubin, alkaline phos-
phatase, and urine analysis, was normal. Her CD4%, CD4Figure 1 (a) Palpable purpuric skin lesions on the right thigh on
the first day of Henoch—Scho¨nlein purpura diagnosis. (b) Palp-
able purpuric skin lesions on the right upper back and shoulder on
the first day of Henoch—Scho¨nlein purpura diagnosis.count, plasma HIV-RNA level, and platelet count at that
time were 21%, 387 cells/mm3, 4.48 log10 copies/ml, and
269  109/l, respectively. According to the 1990 American
College of Rheumatology criteria for the classification
of HSP,5 she was diagnosed with HSP and treated with 2
days of intravenous methylprednisolone (2 mg/kg/day)
followed by 7 days of oral prednisolone (1 mg/kg/day).
The abdominal pain was resolved in 2 days and the rash
in 35 days. With the rapid improvement of her symptoms,
skin biopsy and serum immunoglobulin A (IgA) were not
performed.
Four months after PTI, she developed asymptomatic
thrombocytopenia with a platelet count of 71  109/l. After
7.5 months of PTI, she restarted the same ART due to CD4
decline to 18%, at which time her other laboratory findings
were CD4 count 293 cells/mm3, platelet count 116  109/l,
and plasma HIV-RNA 4.18 log10 copies/ml. Her platelet count
rose spontaneously without ART or other treatments.
Ten weeks after restarting ART, she was clinically well and
her CD4 rose to 24% and CD4 count to 435 cells/mm3, with a
decline of plasma HIV-RNA to 1.7 log10 copies/ml. Her plate-
let count normalized to 216  109/l.
Testing was undertaken in order to exclude a concurrent
hepatitis infection; hepatitis C antibody (anti-HCV) was
found to be negative at 3 months, and HBsAg, HBeAg,
anti-HBs, and anti-HBe were all negative at 5 months after
the onset of HSP.
Discussion
Three months after PTI, this 11-year-old girl developed
severe abdominal pain and palpable purpura consistent with
three of the four diagnostic criteria of HSP according to the
1990 criteria for the classification of HSP: palpable purpura,
less than 20 years of age at disease onset, diffuse abdominal
pain, and histologic changes showing granulocytes in the
walls of arterioles or venules.5 The presence of two or more
criteria yields a sensitivity of 87.1% and a specificity of 87.7%.
There was no precipitating infection before the onset of HSP
in this girl. She did not have hepatitis B or C, which have been
reported as associated causes of HSP in adult patients with
HIV.1,2,4,6 Serum IgA has been found to be increased in some
case reports of HIV and HSP,4 but this was not ascertained in
our patient. She had a dramatic response to methylpredni-
solone and did not have other complications, such as renal
diseases, which is consistent with reports of a more benign
HSP disease in children compared to adults.7—9 Her throm-
bocytopenia prior to starting ARTrecurred 4 months after PTI
and 1 month after the diagnosis of HSP.
HSP is a systemic disorder characterized by leukocyto-
plastic vasculitis involving small vessels of the skin, gastro-
intestinal tract, joints, and kidneys with the deposition of IgA
immune complexes. HIV causes immune dysfunction, often
referred to as a state of inappropriate immune activation,
which results in hypergammaglobulinemia and high circulat-
ing immune complex and the development of autoimmune
diseases.10 HIV may have a direct effect on vascular endothe-
lium. HIV particles have been identified in perivascular tissue
of HIV-infected patients with polyarteritis nodosa.6,11,12 The
association between HIVand HSP has been suggested in a few
case reports. A 26-year-old ART-untreated, HIV-positive man
developed nephritic syndrome and purpura on both lower
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plasmapheresis. After 3 weeks of ART, his symptoms resolved
rapidly coinciding with a rapid reduction of HIV-RNA.1
Another reported case was that of a 23-year-old man with
untreated HIV infection and HBV co-infection who developed
palpable purpura on his limbs with relapsing diarrhea and
arthralgia. His anti-HBc, HBsAg, and HBeAg were positive. He
was treated with recombinant interferon alpha together with
zidovudine, resulting in the rapid disappearance of the
lesions without further relapses.2 The uncontrolled HIV vir-
emia and immune dysfunction in these patients possibly
contributed to HSP. Indeed, viral load rise and CD4 decline
have been associated with immune activation and the man-
ifestation of rheumatic diseases in HIV-infected Chinese
patients.3
PTI is currently not recommended as a standard HIV
treatment strategy. The goal of PTI is to allow patients to
stop ART for a period of time, which may improve their
quality of life and reduce ART-related toxicity, while main-
taining their CD4 at a safe level. PTI has been used in clinical
practice in special circumstances, such as in adolescents
who intend to stop ART on their own without proper mon-
itoring unless PTI is offered to them. Although some recent
adult trials have demonstrated benefits of stopping ART
based on CD4 count,13 the largest PTI trial, Strategy for
Management of Antiretroviral Therapy Trial, showed that PTI
using CD4 cell count as a guide led to a surprising increase in
non-HIV-related serious illnesses.14 It is speculated that the
heightened immune activation following PTI may have been
the cause, and further investigation is underway. Immune
activation has been suggested as a possible cause of recur-
ring thrombocytopenia associated with PTI.15 Low platelet
counts prior to treatment initiation could be a predisposing
factor for thrombocytopenia during PTI. It is believed that
the production of IgG platelet antibody to gp120, which
mimics the structure of GPIIIa platelet membrane, is one
of the causes of HIV-related thrombocytopenia.15 After a
period of well-controlled viremia, when ART is stopped, a
dramatic HIV-RNA rise is seen. This higher HIVantigenic load
causes immune activation by stimulating HIV-specific and
non-specific CD4+ and CD8+ T cell responses, antibody pro-
duction, and innate immune responses.16 In addition, a
significant decline of CD4% and CD4 count in 71 children
with HIV after unplanned treatment interruption has been
reported.17
To our knowledge, this is the first case of HSP in a child
with HIV infection undergoing PTI. Although we could not
clearly ascertain the cause of HSP in this child, HIV- and PTI-
associated immune activation could possibly have contribu-
ted to the development of HSP. We suggest that in HIV-
infected patients undergoing PTI, clinicians be aware of
the possible occurrences of HSP and thrombocytopenia.
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